Drug development for maternal health cannot be left to the whims of the market.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18578567.
- Also identified by DOI 10.1371/journal.pmed.0050140 and PMC identifier 2504051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The<i>PLoS Medicine</i> Editors argue that the current business model of the pharmaceutical industry provides no incentives for the development of new treatments for maternal health, and that political will is needed to support new approaches.
Medical subject headings
- Drug Design
- Health Care Sector
- Maternal Welfare
- Pregnancy Complications